Preview

Качественная клиническая практика

Расширенный поиск

Потребность и потребление антитромбоцитарных препаратов у постинфарктных больных в РФ

Аннотация

В данном анализе проведена оценка потребности и потребления антитромбоцитарных препаратов для лечения постинфарктных состояний, а также дана оценка эпидемиологии постинфарктных состояний в РФ, рассматриваются существующие способы антитромбоцитарной терапии. Проанализированы распространенность ОИМ и число больных перенесших инфаркт миокарда в РФ, которым необходимо принимать антитромбоцитарные препараты. Оценена годовая стоимость применения антитромбоцитарных препаратов для лечения постинфарктных состояний. Подсчитаны возможные затраты общества на лекарственную терапию антитромбоцитарными препаратами постинфарктных состояний при выполнении рекомендаций ВНОК. Приводится анализ потребления антитромбоцитарных препаратов в РФ по данным Таможенного комитета РФ.

Об авторах

Д. Ю. Белоусов
http://www.healtheconomics.ru/
ООО "Центр фармакоэкономических исследований", г. Москва
Россия

генеральный директор

SPIN-код: 6067-9067



О. И. Медников
ООО «Даймонд Вижн», г. Москва
Россия
генеральный директор


Список литературы

1. Alpert J.S., et al. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology. 2000;36:959-969.

2. American Heart Association (AHA). 2001 heart and stroke statistical update. Dallas: American Heart Association. 2000.

3. Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients British Medical Journal. 12 Jan 2002, Vol 324: p 71-86.

4. Barakat K., et al. Acute myocardial infarction in women: contribution of treatment variables to adverse outcome. American Heart Journal. 2000;140:740-746.

5. Braunwald E. Shattuck Lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. New England Journal of Medicine. 1997;337:1360-1369.

6. Capewell S., et al. Trends in case-fatality in 117,718 patients admitted with acute myocardial infarction in Scotland. European Society of Cardiology. 2000;21:1833-1840.

7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329.

8. Chandra N.C., et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Archives of Internal Medicine. 1998;158:981-988.

9. Choudhury L. Myocardial infarction in young patients. American Journal of Medicine. 1999;107:254.

10. Cooper R., et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-3147.

11. CURE Study Investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme. Eur Heart J 2000; 21: 2033-41.

12. Ducimetiere P., et al. Why mortality from heart disease is low in France. British Medical Journal. 2000;320:249-249.

13. Ezzati T.M., et al. Sample design: Third National Health and Nutrition Examination Survey. Vital Health Stat. 1992;1-35.

14. Fonarow G.C., et al. Use of lipid lowering medications at discharge in patients with acute myocardial infarction. Circulation. 2001;103:38-44.

15. Ford E.S., et al. Prevalence of nonfatal coronary heart disease among American adults. American Heart Journal. 2000;139:371-377.

16. Fukiyama K., et al. Incidence and long-term prognosis of initial stroke and acute myocardial infarction in Okinawa, Japan. Hypertension Research. 2000;23:127-135.

17. Furman M.I., et al. Twenty-two year (1975-1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: A multi-hospital, community-wide perspective. Journal of the American- College of Cardiology. 2001;37:1571-1580.

18. Gersh B.J. The changing late prognosis of acute myocardial infarction: implications and mechanisms. European Heart Journal. 1995;16:50-53.

19. Goldberg R.J. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: A community-wide perspective. Journal of the American College of Cardiology. 1999;33:1533-1539.

20. Gunter N., et al. Cooperative cardiovascular project. Journal of the South Carolina Medical Association. 1997;93(5):177-179.

21. Heidenreich P.A., McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. American Journal of Medicine. 2001;110:165-174.

22. Hosoda S., et al. Follow-up of 2,733 patients with myocardial infarction. Japanese Circulation Journal. 1995;59:121-129.

23. Joint Symposium: European Society of Cardiology/American College of Cardiology. Presented at ACC 2001/50th Annual Scientific Session; March 18-21, 2001; Orlando, FL.

24. Kimura Y., et al. Demographic study of first-ever stroke and acute myocardial infarction on Okinawa, Japan. Internal Medicine. 1998;37:736-745.

25. Mehta S.R., Yusuf S., Peters R.J.G. et al for the CURE investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-33.

26. Meier M.A. The new definition of myocardial infarction: what does it mean clinically? Presented at ACC 2001/ 50th. Annual Scientific Session. March 18-21, 2001; Orlando, FL.

27. Nakamura Y., et al. Comparison between Japan and North America in the post-hospital course after recovery from an acute coronary event. International Journal of Cardiology. 1996;55:245-254.

28. National Centre for Social Research. Health Survey of England 1998: cardiovascular disease. Department of Epidemiology and Public Health, Royal Free and University College Medical School The Stationary Office, London. 1998.

29. National Heart, Lung and Blood Institute (NHLBI). Morbidity and Mortality: 2000 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: Public Health Service, National Institutes of Health; 2000:17-35.

30. Olsson L., et al. Validity of a postal questionnaire with regard to the prevalence of myocardial infarction in a general population sample. European Heart Journal. 1989;10:1011-1016.

31. Pepine C.I., et al. Changing myocardial infarction population characteristics: reasons and implications. American Heart Journal. 1997;134:S1.

32. Perez G., et al. Myocardial Infarction in Girona, Spain: attack rate, mortality rate and 28-day case fatality in 1988. Journal of Clinical Epidemiology. 1993;46:1173.

33. Phibbs B., et al. Q-wave and non-Q wave myocardial infarction: a meaningless distinction. Journal of the American College of Cardiology. 1999;33:576-582.

34. Rosamond W.D., et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987-1994. New England Journal of Medicine. 1998;339:861867.

35. Sala J., et al. Improvement in survival after myocardial infarction between 1978-1985 and 1986-1988 in the REGICOR Study. European Heart Journal. 1995;16:779-784.

36. Scrutino D., et al. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. Journal of the American College of Cardiology. 2001;37:1259-1265.

37. Tanabe M., et al. [Epidemiology of acute coronary syndrome]. Nippon Rinsho. 1998;56:2681-2685.

38. The Clopidogrel in Unstable Angina to Prevent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STBsegment elevation. N Engl J Med 2001; 345: 494-502.

39. Tunstall-Pedoe H., et al. Contribution of trends in survival and coronary event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet. 1999;353:1547-1557.

40. United Nations (U.N.), Population Division, Department of Economics and Social Affairs. Sex and age quinquennial 1950-2050 (The 1998 revision), 1998.

41. Vaccarino V., et al. Long-term outcome of myocardial infarction in women and men: a population perspective. American Journal of Epidemiology. 2000;152:965-973.

42. van der Pal-de Bruin K.M., et al. The incidence of suspected myocardial infarction in Dutch general practice in the period 1978-1994. European Heart Journal. 1998;19:429-434.

43. Volmink J.A. Coronary event and case fatality rates in an English population: results of the Oxford Myocardial Infarction Incidence Study. Heart. 1998;80:40

44. Wiesner G., et al. Note on the myocardial infarction scene in the Federal Republic of Germany: prevalence, incidence, trends, comparison between Eastern and Western Germany [Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Pravalenz, Inzidenz, Trend, Ost-West-Vergleich]. Gesundheitswesen. 1999;61:S72-S78.

45. Здоровье населения России и деятельность учреждения здравоохранения в 1999 (2000) г. (статистические материалы). М., 1999 (2000)

46. Импорт антиромбоцитарных средств (2002), ООО 'Даймонд Вижн', www.d-vision.ru

47. Прайс-лист 'ЦВ Протек' от 27 января 2003 г., www.protek.ru

48. Pietro Minuz, Maurizio Degan, Stefania Gaino, Alessandra Meneguzzi, Valeria Zuliani, Clara Lechi Santonastaso, Piero Del Soldato, Alessandro Lechi NCX4016 (NO-aspirin) inhibits thrombox ane biosynthesis and tissue factor expression and activity in human monocytes. Med Sci Monit, 2001; 7(4): 573-577

49. Основы клинической фармакологии и рациональной фармакотерапии, под ред. Ю.Б.Белоусова, М.В.Леоновой, Издательство 'Бионика', М.-2002, стр. 187

50. Рекомендации по лечению острого коронарного синдрома без стойкого подъема сегмента ST на ЭКГ. ВНОК. Российский национальный конгресс кардиологов 11 октября 2001г., www.cardiosite.ru

51. Рекомендации Европейского общества кардиологов Экспертный комитет по разработке практических рекомендаций и проведению методических конференций с целью повышения качества лечения в европейских странах Рекомендации по диагностике и лечению хронической сердечной недостаточности. Сердечная недостаточность. Consilium Medicum. Том 1/N 6/2001, www.consilium-medicum.com/media/heart/01_06/251.shtml

52. -rd International Summit on Atherothrombosis, 12-13 April 2003, Madrid, Spain. Abstract book.


Для цитирования:


Белоусов Д.Ю., Медников О.И. Потребность и потребление антитромбоцитарных препаратов у постинфарктных больных в РФ. Качественная клиническая практика. 2003;(1):60-70.

For citation:


., . . Kachestvennaya klinicheskaya praktika. 2003;(1):60-70.

Просмотров: 25


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)